logo-loader
viewIndia Globalization Capital Inc

India Globalization Capital stock pops after CBD-based Hyalolex drops for Alzheimer’s patients launches in Puerto Rico

The company is holding a doctor-patient education conference on March 30 in San Juan to talk to patients and their families about how Hyalolex is a 'gentler treatment journey' for Alzheimer’s patients

A marijuana plant and bottle of oil
The Maryland-based company is a peculiar mash-up of its legacy infrastructure business, which includes real estate management and its cannabis-focused pharma branch

India Globalization Capital Inc (NYSE:IGC) stock popped Wednesday after the infrastructure-meets-cannabis company said Hyalolex, a cannabis-based product for patients suffering from Alzheimer’s disease, will be available in dispensaries in San Juan, Puerto Rico.

Shares in the Bethesda, Maryland-based company shot up nearly 19% to $2.36.

Hyalolex’s launch comes barely a week after Biogen Inc (NASDAQ:BIIB) and Esai, decided to halt two trials involving a promising new Alzheimer’s drug called aducanumab, which didn’t seem to be working to improve people’s memory.

READ: Short-seller Andrew Left’s Citron Research sets sights on India Globalization Capital

India Globalization is now selling a 30 ml bottle of Hyalolex for $55. The company said it will hold a doctor-patient education conference on March 30 in San Juan to educate patients and their families on how Hyalolex works.

The patent-pending Hyalolex CBD drops are not approved by the US Food and Drug Administration.  

Hyalolex is inspired by the word "hyalos," meaning clear in Greek and delivers micro-doses of cannabinoids from hemp oil, melatonin, and turmeric, designed to “improve the quality of life” for people with Alzheimer's, said the company. Hyalolex also contains THC below the federal limit of .3%.

Separately, the company said it has launched a new website for customers to place orders for wholesale hemp crude extract, hemp distillate, or hemp isolate.

The company earlier said it was plowing money into marketing Serosapse, which the company claims addresses “several endpoints” in Parkinson’s disease including “sleep disorder, anxiety, and dyskinesia.”

India Globalization is a mash-up of a legacy infrastructure business, which includes heavy equipment rental and real estate management, and a cannabis-focused pharmaceutical branch.

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

Quick facts: India Globalization Capital Inc

Price: 0.48 USD

NYSE:IGC
Market: NYSE
Market Cap: $18.87 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Symphony Environmental Technologies has game changing...

Symphony Environmental Technologies PLC (AIM: SYM) CEO Michael Laurier joined Steve Darling from Proactive with news the company has received U.S. Food & Drugs Administration approval or its d2p antimicrobial technology. Laurier discusses what that means for the company and what their...

11 hours, 18 minutes ago

2 min read